Viridian Therapeutics VRDN Stock
Viridian Therapeutics Price Chart
Viridian Therapeutics VRDN Financial and Trading Overview
| Viridian Therapeutics stock price | 13.07 USD |
| Previous Close | 27.67 USD |
| Open | 27.66 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 27.26 - 28.1 USD |
| 52 Week Range | 9.87 - 39 USD |
| Volume | 439.17K USD |
| Avg. Volume | 607.78K USD |
| Market Cap | 1.25B USD |
| Beta (5Y Monthly) | 0.984859 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.44 USD |
VRDN Valuation Measures
| Enterprise Value | 960.8M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.6531444 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 757.72876 |
| Price/Book (mrq) | 5.565096 |
| Enterprise Value/Revenue | 580.894 |
| Enterprise Value/EBITDA | -5.321 |
Trading Information
Viridian Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.984859 |
| 52-Week Change | 157.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 39 USD |
| 52 Week Low | 9.87 USD |
| 50-Day Moving Average | 25.78 USD |
| 200-Day Moving Average | 26.37 USD |
VRDN Share Statistics
| Avg. Volume (3 month) | 607.78K USD |
| Avg. Daily Volume (10-Days) | 551K USD |
| Shares Outstanding | 43.13M |
| Float | 35.26M |
| Short Ratio | 8.24 |
| % Held by Insiders | 1.90% |
| % Held by Institutions | 97.32% |
| Shares Short | 5.69M |
| Short % of Float | 13.63% |
| Short % of Shares Outstanding | 13.18% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10936.39% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -39.68% |
| Return on Equity (ttm) | -66.64% |
Income Statement
| Revenue (ttm) | 1.65M USD |
| Revenue Per Share (ttm) | 0.05 USD |
| Quarterly Revenue Growth (yoy) | -54.60% |
| Gross Profit (ttm) | -99122000 USD |
| EBITDA | -180568000 USD |
| Net Income Avi to Common (ttm) | -172332000 USD |
| Diluted EPS (ttm) | -4.68 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 373.86M USD |
| Total Cash Per Share (mrq) | 8.67 USD |
| Total Debt (mrq) | 6.27M USD |
| Total Debt/Equity (mrq) | 1.79 USD |
| Current Ratio (mrq) | 12.931 |
| Book Value Per Share (mrq) | 5.008 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -134768992 USD |
| Levered Free Cash Flow (ttm) | -73191872 USD |
Profile of Viridian Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 221 Crescent Street |
| ZIP | 02453 |
| Phone | 617 272 4600 |
| Website | https://www.viridiantherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 86 |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.
Q&A For Viridian Therapeutics Stock
What is a current VRDN stock price?
Viridian Therapeutics VRDN stock price today per share is 13.07 USD.
How to purchase Viridian Therapeutics stock?
You can buy VRDN shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Viridian Therapeutics?
The stock symbol or ticker of Viridian Therapeutics is VRDN.
Which industry does the Viridian Therapeutics company belong to?
The Viridian Therapeutics industry is Biotechnology.
How many shares does Viridian Therapeutics have in circulation?
The max supply of Viridian Therapeutics shares is 81.48M.
What is Viridian Therapeutics Price to Earnings Ratio (PE Ratio)?
Viridian Therapeutics PE Ratio is now.
What was Viridian Therapeutics earnings per share over the trailing 12 months (TTM)?
Viridian Therapeutics EPS is -3.07 USD over the trailing 12 months.
Which sector does the Viridian Therapeutics company belong to?
The Viridian Therapeutics sector is Healthcare.
Viridian Therapeutics VRDN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17601.05 USD — |
+0.87
|
8.38B USD — | 17181.27 USD — | 17716.52 USD — | — - | 8.38B USD — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2175.44 USD — |
+1.63
|
— — | 2111.36 USD — | 2178.11 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2828.94 USD — |
+1.53
|
— — | 2747.63 USD — | 2838.03 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 942.47 USD — |
+1.43
|
— — | 920.56 USD — | 943.62 USD — | — - | — — |
- {{ link.label }} {{link}}